摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-<1-(3,4-dimethoxyphenyl)-2-phenylethyl>formamide | 80235-73-0

中文名称
——
中文别名
——
英文名称
N-<1-(3,4-dimethoxyphenyl)-2-phenylethyl>formamide
英文别名
1-(3,4-Dimethoxy-phenyl)-2-phenyl-1-formylaminoaethan;N-Formyl-2-phenyl-1-<3,4-dimethoxy-phenyl>-aethylamin;N-(3,4-dimethoxy-bibenzyl-α-yl)-formamide;N-(3,4-Dimethoxy-bibenzyl-α-yl)-formamid;N-[1-(3,4-dimethoxyphenyl)-2-phenylethyl]formamide
N-<1-(3,4-dimethoxyphenyl)-2-phenylethyl>formamide化学式
CAS
80235-73-0
化学式
C17H19NO3
mdl
——
分子量
285.343
InChiKey
NHAVVZIPYLKCPA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    21
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    47.6
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-<1-(3,4-dimethoxyphenyl)-2-phenylethyl>formamide硫酸三氯化铁 作用下, 以 甲醇二氯甲烷 为溶剂, 反应 0.5h, 生成 3,4-dihydro-3-(3,4-dimethoxyphenyl)isoquinoline
    参考文献:
    名称:
    A modified Bischler-Napieralski procedure for the synthesis of 3-aryl-3,4-dihydroisoquinolines
    摘要:
    A modification of the Bischler-Napieralski reaction for the cyclization of (1,2-diphenylethyl)amides to the 3-aryl-3,4-dihydroisoquinolines is presented. Elimination of the amide group as the nitrile via the retro-Ritter reaction is avoided by its conversion to an N-acyliminium intermediate with oxalyl chloride-FeCl3. Removal of the oxalyl group in refluxing MeOH-sulfuric acid provides the 3,4-dihydroisoquinolines in moderate to high yields. The method is also highly effective with (2-phenylethyl)amides.
    DOI:
    10.1021/jo00021a014
  • 作为产物:
    参考文献:
    名称:
    Catecholamine surrogates useful as .beta..sub.3 agonists
    摘要:
    公式为##STR1##的化合物或其药学上可接受的盐,其中:A是键,--(CH.sub.2).sub.n --或--CH(B)--,其中n是1到3的整数,B是--CN,--CON(R.sup.9)R.sup.9'或--CO.sub.2 R.sup.7;R.sup.1是较低的烷基,芳基或芳基烷基;R.sup.2是氢,羟基,烷氧基,--CH.sub.2 OH,氰基,--C(O)OR.sup.7,--CO.sub.2 H,--CONH.sub.2,四唑基,--CH.sub.2 NH.sub.2或卤素;##STR2## R.sup.3是氢,烷基,杂环或R.sup.4是氢,烷基或B;R.sup.5,R.sup.5',R.sup.8,R.sup.8'或R.sup.8"独立地是氢,烷氧基,较低烷基,卤素,--OH,--CN,--(CH.sub.2).sub.n NR.sup.6 COR.sup.7,--CON(R.sup.6)R.sup.6',--CON(R.sup.6)OR.sup.6',--CO.sub.2 R.sup.6,--SR.sup.7,--SOR.sup.7,--SO.sub.2 R.sup.7,--N(R.sup.6)SO.sub.2 R.sup.1,--N(R.sup.6)R.sup.6',--NR.sup.6 COR.sup.7,--OCH.sub.2 CON(R.sup.6)R.sup.6',--OCH.sub.2 CO.sub.2 R.sup.7或芳基;或R.sup.5和R.sup.5'或R.sup.8和R.sup.8'可以与它们连接的碳原子一起形成芳基或杂环;R.sup.6和R.sup.6'独立地是氢或较低烷基;R.sup.7是较低烷基;R.sup.9是氢,较低烷基,烷基,环烷基,芳基烷基,芳基,杂芳基;或R.sup.9和R.sup.9'可以与它们连接的氮原子一起形成杂环;但是当A是键或--(CH.sub.2).sub.n且R.sup.3是氢或未取代烷基时,R.sup.4是B或取代烷基。这些化合物是β.sub.3肾上腺素受体激动剂,因此在糖尿病、肥胖症和胃肠疾病的治疗中很有用。
    公开号:
    US05776983A1
点击查看最新优质反应信息

文献信息

  • Catecholamine surrogates useful as .beta..sub.3 agonists
    申请人:Bristol-Myers Squibb Company
    公开号:US05776983A1
    公开(公告)日:1998-07-07
    Compounds of the formula ##STR1## or pharmaceutically acceptable salts thereof wherein: A is a bond, --(CH.sub.2).sub.n -- or --CH(B)--, where n is an integer of 1 to 3 and B is --CN, --CON(R.sup.9)R.sup.9' or --CO.sub.2 R.sup.7 ; R.sup.1 is lower alkyl, aryl or arylalkyl; R.sup.2 is hydrogen, hydroxy, alkoxy, --CH.sub.2 OH, cyano, --C(O)OR.sup.7, --CO.sub.2 H, --CONH.sub.2, tetrazole, --CH.sub.2 NH.sub.2 or halogen; ##STR2## R.sup.3 is hydrogen, alkyl, heterocycle or R.sup.4 is hydrogen, alkyl or B; R.sup.5, R.sup.5', R.sup.8, R.sup.8' or R.sup.8" are independently hydrogen, alkoxy, lower alkyl, halogen, --OH, --CN, --(CH.sub.2).sub.n NR.sup.6 COR.sup.7, --CON(R.sup.6)R.sup.6', --CON(R.sup.6)OR.sup.6', --CO.sub.2 R.sup.6, --SR.sup.7, --SOR.sup.7, --SO.sub.2 R.sup.7, --N(R.sup.6)SO.sub.2 R.sup.1, --N(R.sup.6)R.sup.6', --NR.sup.6 COR.sup.7, --OCH.sub.2 CON(R.sup.6)R.sup.6', --OCH.sub.2 CO.sub.2 R.sup.7 or aryl; or R.sup.5 and R.sup.5' or R.sup.8 and R.sup.8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R.sup.6 and R.sup.6' are independently hydrogen or lower alkyl; and R.sup.7 is lower alkyl; R.sup.9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R.sup.9 and R.sup.9' may together with the nitrogen atom to which they are attached form a heterocycle; with the proviso that when A is a bond or --(CH.sub.2).sub.n and R.sup.3 is hydrogen or unsubstituted alkyl, then R.sup.4 is B or substituted alkyl. These compounds are beta.sub.3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.
    公式为##STR1##的化合物或其药学上可接受的盐,其中:A是键,--(CH.sub.2).sub.n --或--CH(B)--,其中n是1到3的整数,B是--CN,--CON(R.sup.9)R.sup.9'或--CO.sub.2 R.sup.7;R.sup.1是较低的烷基,芳基或芳基烷基;R.sup.2是氢,羟基,烷氧基,--CH.sub.2 OH,氰基,--C(O)OR.sup.7,--CO.sub.2 H,--CONH.sub.2,四唑基,--CH.sub.2 NH.sub.2或卤素;##STR2## R.sup.3是氢,烷基,杂环或R.sup.4是氢,烷基或B;R.sup.5,R.sup.5',R.sup.8,R.sup.8'或R.sup.8"独立地是氢,烷氧基,较低烷基,卤素,--OH,--CN,--(CH.sub.2).sub.n NR.sup.6 COR.sup.7,--CON(R.sup.6)R.sup.6',--CON(R.sup.6)OR.sup.6',--CO.sub.2 R.sup.6,--SR.sup.7,--SOR.sup.7,--SO.sub.2 R.sup.7,--N(R.sup.6)SO.sub.2 R.sup.1,--N(R.sup.6)R.sup.6',--NR.sup.6 COR.sup.7,--OCH.sub.2 CON(R.sup.6)R.sup.6',--OCH.sub.2 CO.sub.2 R.sup.7或芳基;或R.sup.5和R.sup.5'或R.sup.8和R.sup.8'可以与它们连接的碳原子一起形成芳基或杂环;R.sup.6和R.sup.6'独立地是氢或较低烷基;R.sup.7是较低烷基;R.sup.9是氢,较低烷基,烷基,环烷基,芳基烷基,芳基,杂芳基;或R.sup.9和R.sup.9'可以与它们连接的氮原子一起形成杂环;但是当A是键或--(CH.sub.2).sub.n且R.sup.3是氢或未取代烷基时,R.sup.4是B或取代烷基。这些化合物是β.sub.3肾上腺素受体激动剂,因此在糖尿病、肥胖症和胃肠疾病的治疗中很有用。
  • Towards the rehabilitation of the Leuckart reductive amination reaction using microwave technology
    作者:André Loupy、Daphné Monteux、Alain Petit、Jesús Ma Aizpurua、Esther Domínguez、Claudio Palomo
    DOI:10.1016/0040-4039(96)01865-5
    日期:1996.11
    amination of carbonyl compounds was dramatically enhanced with respect to conventional heating by a specific microwave effect when the reaction was performed, under solvent-free conditions, in a monomode microwave reactor. Excellent isolated yields (up to 97%) were attained within short reaction times (typically, 30 minutes)
    当在无溶剂条件下在单模微波反应器中进行反应时,通过特定的微波效应,相对于常规加热,羰基化合物的Leuckart还原胺化得到了显着增强。在较短的反应时间内(通常为30分钟)即可获得出色的分离产率(高达97%)
  • Structure and stereochemistry of cyclodimers obtained by acid treatment of trans-stilbenes and of N-1,2-diarylethylamides
    作者:José M. Aguirre、Elba N. Alesso、Graciela Y. Moltrasio Iglesias
    DOI:10.1039/a900282k
    日期:——
    The reaction of trans-stilbenes and N-1,2-diarylethylamides with ethyl polyphosphate affords indanes and tetralins with three stereogenic centres. The structural and configurational assignment of the cyclodimers is based mainly on the NMR and MS data. A possible transition state for the reaction is discussed.
    反式二苯乙烯和 N-1,2-二乙基酰胺与多磷酸乙酯反应生成具有三个立体中心的茚和四氢萘。环二聚体的结构和构型分配主要基于核磁共振和质谱数据。讨论了该反应可能的过渡态。
  • Catecholamine surrogates useful as B3 agonists
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:EP0659737A2
    公开(公告)日:1995-06-28
    Compounds of the formula or pharmaceutically acceptable salts thereof wherein: A is a bond, -(CH2)n- or -CH(B)-, where n is an integer of 1 to 3 and B is -CN, -CON(R9)R9' or -C02R7; R1 is lower alkyl, aryl or arylalkyl; R2 is hydrogen, hydroxy, alkoxy, -CH20H, cyano, -C(O)OR7 , -C02H, -CONH2, tetrazole, -CH2NH2 or halogen; R3 is hydrogen, alkyl, heterocycle or R4 is hydrogen, alkyl or B; R5, R5', R8, R8' or R8'' are independently hydrogen, alkoxy, lower alkyl, halogen, -OH, -CN, -(CH2)-nNR6COR7, -CON(R6)R6', -CON(R6)OR6', -C02R6, -SR7, -SOR7, -S02R7, -N(R6)SO2R1, -N(R6)R6', -NR6COR7, -OCH2CON(R6)R6', -OCH2CO2R7 or aryl; or R5 and R5' or R8 and R8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R6 and R6' are independently hydrogen or lower alkyl; and R7 is lower alkyl; R9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R9 and R9' may together with the nitrogen atom to which they are attached form a hetocycle; with the proviso that when A is a bond or -(CH2)n and R3 is hydrogen or unsubstituted alkyl, then R4 is B or substituted alkyl. These compounds are beta3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.
    式中的化合物 或其药学上可接受的盐类,其中 A 是键、-(CH2)n- 或 -CH(B)-,其中 n 是 1 至 3 的整数,B 是 -CN、-CON(R9)R9' 或 -C02R7; R1 是低级烷基、芳基或芳烷基; R2 是氢、羟基、烷氧基、-CH20H、氰基、-C(O)OR7、-C02H、-CONH2、四唑、-CH2NH2 或卤素; R3 是氢、烷基、杂环或卤素。 R4 是氢、烷基或 B; R5、R5'、R8、R8' 或 R8'' 独立地为氢、烷氧基、低级烷基、卤素、-OH、-CN、-(CH2)-nNR6COR7、-CON(R6)R6'、-C02R6、-SR7、-SOR7、-S02R7、-N(R6)SO2R1、-N(R6)R6'、-NR6COR7、-OCH2CON(R6)R6'、-OCH2CO2R7 或芳基;或 R5 和 R5' 或 R8 和 R8'可与它们所连接的碳原子一起形成芳基或杂环; R6 和 R6'独立地为氢或低级烷基;以及 R7 是低级烷基; R9是氢、低级烷基、烷基、环烷基、芳烷基、芳基、杂芳基;或 R9和R9'可与它们所连接的氮原子一起形成一个杂环;但当A是键或-(CH2)n且R3是氢或未取代的烷基时,则R4是B或取代的烷基。这些化合物是β3肾上腺素能受体激动剂,因此可用于治疗糖尿病、肥胖症和胃肠道疾病等。
  • Application of the Intramolecular α-Amidoalkylation Reaction for the Synthesis of 3- and 1,3-Alkyl(aryl) 2-Formyltetrahydroisoquinolines
    作者:Atanas P. Venkov、Ilian I. Ivanov
    DOI:10.1080/00397919308011269
    日期:1993.6
    3- and 1,3-Alkyl(aryl) 2-Formyltetrahydroisoquinolines 6 are obtained by the application of the intramolecular is-proportional-to -amidoalkylation reaction from 1-Alkyl(Aryl)-2-Arylethylformamides 2 and aldehydes in acidic medium.
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 银松素 铒(III) 离子载体 I 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯 钠3-(4-甲氧基苯基)-2-苯基丙烯酸酯 重氮基乙酸胆酯酯 醋酸(R)-(+)-2-羟基-1,2,2-三苯乙酯 酸性绿16 邻氯苯基苄基酮 那碎因盐酸盐 那碎因[鹼] 达格列净杂质54 辛那马维林 赤藓型-1,2-联苯-2-(丙胺)乙醇 赤松素 败脂酸,丁基丙-2-烯酸酯,甲基2-甲基丙-2-烯酸酯,2-甲基丙-2-烯酸